Background: Patients with type-2 diabetes are at risk for treatment- and disease-related complications. Little is known about the interrelation of hypoglycaemia and co-morbid vascular disease (VD), defined as coronary heart disease, stroke and peripheral arterial disease.
Hypothesis: Hypoglycaemia is associated with co-morbid VD in diabetic patients.
Methods: DiaRegis is a prospective registry that included patients with type-2 diabetes in 2009/2010. Metric variables are displayed as median and quartiles. For the comparison of patients with or without VD Odds Ratios (OR) were determined from univariate analyses and adjusted for differences in patient characteristics (multivariable analysis).
Results: Data on hypoglycaemia and VD within the last 12 months were available for 3741 patients (98.2%) with a median (IQR) age of 65.9 (57.6–72.9) years; 46.7% were female. VD patients (n = 909; 24.3%) were older (70.7 vs 63.9 years; p < 0.0001), less often female (33.6% vs 50.9%; p < 0.0001) and had had diabetes for a longer duration (6.4 vs 5.4 years; p < 0.0001). Mean cholesterol (total, HDL and LDL) was also slightly lower (p < 0.0001). Glycaemic control (HbA1c, fasting and postprandial glucose) was comparable. VD patients received less metformin (80.7 vs 85.2%; p < 0.01) and more sulfonylureas (31.8 vs 27.6%; p < 0.05). There was an increased incidence of symptomatic hypoglycaemia with or without requiring help and with a need for medical assistance. After adjusting a number of baseline variables the rates of symptomatic hypoglycaemias with help remained significantly increased (OR 3.73 (95% CI 1.31–10.65) in patients with VD.
Conclusions: As hypothesized there is a strong association between the incidence of hypoglycaemia and vascular disease at comparable glycaemic control, which confirms prior randomized controlled trial data suggesting an interrelationship between hypoglycaemia and vascular disease.
TurnbullFMAbrairaCAndersonRJByingtonRPChalmersJPDuckworthWC. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia2009; 52: 2288–2298.
2.
DluhyRGMcMahonGT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med2008; 358: 2630–2633.
3.
BondsDEMillerMEBergenstalRMBuseJBByingtonRPCutlerJA. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010; 340: b4909–b4909.
4.
ZoungasSPatelAChalmersJde GalanBELiQBillotL. Severe hypoglycemia and risks of vascular events and death. N Engl J Med2010; 363: 1410–1418.
5.
CurrieCJPetersJRTynanAEvansMHeineRJBraccoOL. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet2010; 375: 481–489.
6.
BramlagePBinzCGittAKKreklerMPlateTDeegE. Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) – study protocol and patient characteristics at baseline. Cardiovasc Diabetol2010; 9: 53–53.
7.
GaedePLund-AndersenHParvingHHPedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580–591.
8.
PatelAMacMahonSChalmersJNealBBillotLWoodwardM. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008; 358: 2560–2572.
9.
GersteinHCMillerMEByingtonRPGoffDCJrBiggerJTBuseJB. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008; 358: 2545–2559.
10.
UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352: 837–853.
11.
KinseyJ. Incidence and cause of death in shock therapy. Arch Neurol Psychiatry1941; 46: 55–58.
12.
GilbertRGoldzieherJ. The mechanism and prevention of cardiovascular changes due to insulin. Ann Intern Med1946; 25: 928–940.
13.
PartamianJOBradleyRF. Acute myocardial infarction in 258 cases of diabetes. Immediate mortality and five-year survival. N Engl J Med1965; 273: 455–461.
14.
DesouzaCSalazarHCheongBMurgoJFonsecaV. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care2003; 26: 1485–1489.
15.
SvenssonAMMcGuireDKAbrahamssonPDellborgM. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J2005; 26: 1255–1261.
16.
FismanEZMotroMTenenbaumALeorJBoykoVMandelzweigL. Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up. Eur J Cardiovasc Prev Rehabil2004; 11: 135–143.
17.
UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998; 352: 854–865.
18.
MeinertCLKnatterudGLProutTEKlimtCR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes1970; 19(Suppl): 789–830.
19.
PlutzkyJ. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep2000; 2: 327–335.
20.
MarxNSukhovaGMurphyCLibbyPPlutzkyJ. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol1998; 153: 17–23.
21.
WatanabeYSunayamaSShimadaKSawanoMHoshiSIwamaY. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb2000; 7: 159–163.
22.
MarxNMackmanNSchonbeckUYilmazNHombachVLibbyP. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation2001; 103: 213–219.
